Clinical Study
High Prevalence of Antinuclear Antibodies in Children with Thyroid Autoimmunity
Table 1
(a) Clinical and laboratory features of the patients at inclusion. (b) Clinical and laboratory features of ANA-positive and ANA-negative children.
| (a) |
| | Characteristic | Patients () |
| | F/M | 76/17 | CLT ()
| 86 | | GD () | 7 | | Age at diagnosis (mean years ± SD) | | Age at sampling (mean years ± SD)
| | | Duration of disease (mean years ± SD) | | | CLT on LT4 treatment (/%) | 47/86 (54.6%) | | TSH (µIU/mL ± SD) | | | TPOAb (IU/mL ± SD) | | TgAb (IU/mL ± SD)
| | | Associated autoimmune disease in children (/%) | 20/93 (21%) | | Associated autoimmune disease in CLT (/%) | 17/86 (20%) | | Associated autoimmune disease in GD (/%) | 3/7 (43%) | | Autoimmune disease in parents (/%) | 43/186 (23%)
|
|
|
| (b) |
| | Patients | ANA positive () | ANA negative () | |
| | F/M | 56/10 | 20/7 | |
| | CLT (/%) | 62 (72%) | 24 (28%) | 0.7
| | GD (%) | 4 (57%) | 3 (43%) | 0.7 | Age at diagnosis (mean years ± SD)
| | | 0.61 | | Age at sampling (mean years ± SD) | | | 0.32 | | TSH (µIU/mL ± SD) | | | 0.2 | | TPOAb (IU/mL ± SD) | | | 0.61 | | TgAb (IU/mL ± SD) | | | 0.85 | | LT4 therapy (CLT) (/%) | 31/62 (50%) | 16/27 (66%) | 0.99 |
|
|
F/M: females/males; CLT: chronic lymphocytic thyroiditis; GD: graves’ disease; TSH: thyroid stimulating hormone; TPOAb: thyroid peroxidase antibodies; TgAb: thyroglobulin antibodies; LT4: L-thyroxine.
|
